Evidence map›Paper›PMID 35791659›Full record

ArticleAcute and critical care2022

Muscle Growth and Anabolism in Intensive Care Survivors (GAINS) trial: a pilot randomised controlled trial.

Matthew H Anstey, Rashmi Rauniyar, Ethan Fitzclarence, Natalie Tran, Emma Osnain, Bianca Mammana, Angela Jacques, Robert N Palmer, Andrew Chapman, Bradley Wibrow

Registry-linked trialOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acute and critical care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06592144 (TESTO-TRIAL), which is not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06592144 phase4active not recruitingnot on this mapstarted 2024, after this paper: background citation

TESTO-TRIAL: Randomized Clinical Trial on the Use of Testosterone in Critically Ill Patients

TypeinterventionalSponsorLeticia Maria Defendi Barboza MarsonRan2024 to 2026Enrolled94ConditionsWeaning Failure, Muscle Weakness, Mechanical Ventilation Complication, ICU Acquired WeaknessArmsTestosterone cypionate (200mg/3ml), Sesame oil (3ml)
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. A review of the role of testosterone in the care of the critically ill patient.The Southern African journal of critical care : the official journal of the Critical Care Society · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Matthew H AnsteyDepartment of Intensive Care, Sir Charles Gairdner Hospital, Perth, Australia.
Rashmi RauniyarDepartment of Intensive Care, Sir Charles Gairdner Hospital, Perth, Australia.
Ethan FitzclarenceDepartment of Intensive Care, Sir Charles Gairdner Hospital, Perth, Australia.
Natalie TranDepartment of Intensive Care, Sir Charles Gairdner Hospital, Perth, Australia.
Emma OsnainDepartment of Intensive Care, Sir Charles Gairdner Hospital, Perth, Australia.
Bianca MammanaDepartment of Intensive Care, Sir Charles Gairdner Hospital, Perth, Australia.
Angela JacquesDepartment of Intensive Care, Sir Charles Gairdner Hospital, Perth, Australia.
Robert N PalmerDepartment of Intensive Care, Sir Charles Gairdner Hospital, Perth, Australia.
Andrew ChapmanDepartment of Intensive Care, Royal Perth Hospital, Perth, Australia.
Bradley WibrowDepartment of Intensive Care, Sir Charles Gairdner Hospital, Perth, Australia.
Sir Charles Gairdner Hospital · AURoyal Perth Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo explore the feasibility, safety, and potential benefits of administration of the anabolic steroid nandrolone to patients in the recovery phase from critical illness weakness.

methodsIn this phase II, double blind, randomized, controlled trial, adult critically ill patients admitted to one of two tertiary Intensive Care Units in Western Australia for longer than 7 days with significant weakness were enrolled. Patients received nandrolone (200 mg males, 100 mg females) intramuscularly or placebo weekly for up to 3 weeks in addition to standard care. The primary outcome measures were improvement in grip strength, Medical Research Council muscle strength sum score, and functional activity level (Chelsea critical care assessment tool [CPAx]).

resultsA total of 22 patients was enrolled between September 2017 and May 2019. No significant adverse events were detected. Median grip strength change was non-significantly greater in the nandrolone group (8.5 vs. 13.0, P=0.185), while hospital length of stay (36 vs. 26 days, P=0.023) and duration of mechanical ventilation (377 vs. 168, P=0.032) were lower. The discharge CPAx and intensive care unit mobility scores were higher in the nandrolone group, although there was no difference in the change in CPAx score (17.0 vs. 17.7, P=0.865). There were no changes in ultrasound-detected muscle thickness between the two groups.

conclusionsIn patients with prolonged critical illness, nandrolone appears to be safe. However, a larger study, potentially combined with resistance exercise, is needed to definitively address the potential benefits of nandrolone.

Indexed as

androgenscritical illnessintensive caremuscle strengthnandrolonequality of life

Identifiers

PMID35791659
PMCPMC9475160
OpenAlexW4284694341

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.